JP2005506290A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506290A5 JP2005506290A5 JP2002570969A JP2002570969A JP2005506290A5 JP 2005506290 A5 JP2005506290 A5 JP 2005506290A5 JP 2002570969 A JP2002570969 A JP 2002570969A JP 2002570969 A JP2002570969 A JP 2002570969A JP 2005506290 A5 JP2005506290 A5 JP 2005506290A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- cancer
- compound
- residue
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- -1 monosubstituted amino Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000005431 alkyl carboxamide group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000005432 dialkylcarboxamide group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims 1
- 208000026292 Cystic Kidney disease Diseases 0.000 claims 1
- 241000790917 Dioxys <bee> Species 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27475101P | 2001-03-07 | 2001-03-07 | |
| PCT/US2002/007001 WO2002072009A2 (en) | 2001-03-07 | 2002-03-07 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506290A JP2005506290A (ja) | 2005-03-03 |
| JP2005506290A5 true JP2005506290A5 (enExample) | 2005-12-22 |
Family
ID=23049469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002570969A Pending JP2005506290A (ja) | 2001-03-07 | 2002-03-07 | 癌および他の増殖性疾患を処置するための複素環式誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7153875B2 (enExample) |
| EP (1) | EP1385465A4 (enExample) |
| JP (1) | JP2005506290A (enExample) |
| AU (1) | AU2002252227A1 (enExample) |
| BR (1) | BR0207846A (enExample) |
| CA (1) | CA2440184A1 (enExample) |
| EA (1) | EA200300982A1 (enExample) |
| IL (1) | IL157740A0 (enExample) |
| MX (1) | MXPA03008117A (enExample) |
| NO (1) | NO20033883L (enExample) |
| PL (1) | PL373912A1 (enExample) |
| WO (1) | WO2002072009A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2383347A1 (en) | 1999-08-31 | 2001-03-08 | Maxia Pharmaceuticals, Inc. | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
| WO2002072009A2 (en) | 2001-03-07 | 2002-09-19 | Maxia Pharmaceuticals, Inc. | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
| US7265139B2 (en) * | 2001-03-08 | 2007-09-04 | Incyte San Diego Inc. | RXR activating molecules |
| EP1421061A4 (en) * | 2001-08-17 | 2004-12-22 | Incyte San Diego Inc | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA |
| JP2005513026A (ja) * | 2001-11-15 | 2005-05-12 | インサイト サン ディエゴ インコーポレイテッド | 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環 |
| CA2468745A1 (en) | 2001-11-30 | 2003-06-12 | The Burnham Institute | Induction of apoptosis in cancer cells |
| US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US7102000B2 (en) * | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| US7714139B2 (en) * | 2003-03-27 | 2010-05-11 | Lankenau Institute For Medcial Research | IDO inhibitors and methods of use |
| FR2856401B1 (fr) * | 2003-06-20 | 2010-02-12 | Galderma Res & Dev | Nouveaux composes modulateurs des recepteurs de type ppargamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| DE10351744A1 (de) * | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| US7122700B2 (en) | 2004-07-30 | 2006-10-17 | Xerox Corporation | Arylamine processes |
| PL1868980T3 (pl) * | 2005-04-08 | 2011-01-31 | Galderma Res & Dev | Nowy sposób wytwarzania kwasu 6-[3-(1-adamantylo)-4-metoksyfenylo]-2-naftoesowego |
| FR2884248B1 (fr) * | 2005-04-08 | 2007-05-18 | Galderma Res & Dev | Nouveau procede de preparation de l'acide 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoique |
| KR100814109B1 (ko) * | 2006-01-09 | 2008-03-14 | 한국생명공학연구원 | 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물 |
| CL2007000995A1 (es) * | 2006-04-11 | 2008-06-27 | Smithkline Beecham Corp | Compuestos derivados de tiazolidinadiona; composicion farmaceutica; y uso para tratar uno o mas estados de enfermedad seleccionada entre trastornos autoinmunes, enfermedad inflamatoria, cardiovascular y neurodegenerativa entre otras. |
| US20080255115A1 (en) * | 2007-04-11 | 2008-10-16 | Michael Gerard Darcy | Thiazolidinedione derivatives as pi3 kinase inhibitors |
| US7592342B2 (en) * | 2007-05-10 | 2009-09-22 | Smithkline Beecham Corporation | Quinoxaline derivatives as PI3 kinase inhibitors |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| AU2008326309C1 (en) | 2007-11-21 | 2015-03-12 | Decode Genetics Ehf | Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders |
| JP2011505341A (ja) * | 2007-11-21 | 2011-02-24 | デコード ジェネティクス イーエイチエフ | 炎症性、心血管およびｃｎｓ障害を治療するビアリールｐｄｅ４抑制剤 |
| CN102558088A (zh) * | 2010-12-31 | 2012-07-11 | 中国科学院上海药物研究所 | 联苯亚甲基-2-硫代-4-噻唑酮类化合物及其制备方法和用途 |
| KR102922092B1 (ko) * | 2021-12-21 | 2026-02-03 | 주식회사 메디픽바이오 | 치환된 티아졸리딘디온 유도체 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| JP2024546175A (ja) * | 2021-12-21 | 2024-12-17 | メディフィック インク | 置換されたチアゾリジンジオン誘導体化合物およびこれを含む癌の予防または治療用の薬学的組成物 |
| US12115148B1 (en) | 2024-05-10 | 2024-10-15 | Imam Mohammad Ibn Saud Islamic University | 3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-5-(2-hydroxy-5-nitrobenzylidene)thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4051842A (en) | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
| DE2626348C3 (de) | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
| JPS5538359A (en) | 1978-09-12 | 1980-03-17 | Hamari Yakuhin Kogyo Kk | Preparation of 2-(3-benzoylphenyl)-propionic acid |
| US4383529A (en) | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
| IL72684A (en) | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
| US4931279A (en) | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4713244A (en) | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| CA1325222C (en) | 1985-08-23 | 1993-12-14 | Lederle (Japan), Ltd. | Process for producing 4-biphenylylacetic acid |
| JP2539504B2 (ja) | 1987-03-11 | 1996-10-02 | 鐘淵化学工業株式会社 | ヒドロキシスチレン誘導体 |
| FI91869C (fi) * | 1987-03-18 | 1994-08-25 | Tanabe Seiyaku Co | Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi |
| US5330998A (en) | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
| US5223522A (en) | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| IE62214B1 (en) | 1988-05-25 | 1995-01-11 | Warner Lambert Co | Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents |
| FI940306A0 (fi) | 1991-07-22 | 1994-01-21 | Pfizer | Menetelmä kiraalisten tiatsolidiini-2,4-dionijohdannaisten synteesissä tarvittavien välituotteiden valmistamiseksi |
| US5780676A (en) | 1992-04-22 | 1998-07-14 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
| ATE195716T1 (de) | 1992-04-22 | 2000-09-15 | Ligand Pharm Inc | Retinoid-x rezeptor selektive verbindungen |
| CZ181493A3 (en) | 1992-09-10 | 1994-03-16 | Lilly Co Eli | The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease |
| CA2149882A1 (en) | 1992-11-25 | 1994-06-09 | Magnus Pfahl | Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression |
| US5691376A (en) | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
| MX9603414A (es) | 1994-02-17 | 1997-03-29 | American Home Prod | Derivados de bifenilo sustituidos como inhibidores de fosfodiesterasa. |
| JPH09136877A (ja) | 1995-06-16 | 1997-05-27 | Takeda Chem Ind Ltd | 複素環化合物、その製造法及び用途 |
| JP2000506489A (ja) | 1995-07-17 | 2000-05-30 | センタ インタナショナル ドゥ リシェルシェ デルマトロジーク セ イ エール デ ガルデルマ | Ａｈｐｎを用いる癌の治療方法 |
| JP2000511875A (ja) | 1996-06-19 | 2000-09-12 | ドクター・レディーズ・リサーチ・ファウンデーション | 抗糖尿病活性を増強されたトログリタゾンの新規な多形型及びそれらの製造方法 |
| CZ3499A3 (cs) | 1996-07-08 | 1999-11-17 | Galderma Research & Development, S. N. C. | Adamantylová sloučenina, její použití a farmaceutický prostředek ji obsahující |
| WO1999009965A2 (en) | 1997-08-21 | 1999-03-04 | Takeda Chemical Industries, Ltd. | Anti-inflammatory agent |
| US5972986A (en) | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| WO1999024415A1 (en) | 1997-11-12 | 1999-05-20 | Institute Of Medicinal Molecular Design, Inc. | Retinoid receptor agonists |
| US6262044B1 (en) * | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
| US6331633B1 (en) | 1998-05-08 | 2001-12-18 | Calyx Therapeutics Inc. | Heterocyclic analogs of diphenylethylene compounds |
| JP2002523371A (ja) | 1998-08-21 | 2002-07-30 | バイロファーマ・インコーポレイテッド | ウイルス感染および関連疾患を治療または予防するための化合物、組成物および方法 |
| WO2000018748A1 (en) | 1998-09-30 | 2000-04-06 | Roche Diagnostics Gmbh | Rhodanine derivatives for the treatment and prevention of metabolic bone disorders |
| WO2000032598A1 (en) | 1998-12-04 | 2000-06-08 | Structural Bioinformatics Inc. | Methods and compositions for treating inflammatory diseases utilizing inhibitors of tumor necrosis factor activity |
| WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
| US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
| CA2383347A1 (en) | 1999-08-31 | 2001-03-08 | Maxia Pharmaceuticals, Inc. | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
| AU767923C (en) | 1999-11-12 | 2005-03-24 | Fujimoto Co., Ltd. | Novel 2-(N-cyanoimino)thiazolidin-4-one derivatives |
| FR2812876B1 (fr) | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| WO2002072009A2 (en) | 2001-03-07 | 2002-09-19 | Maxia Pharmaceuticals, Inc. | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
| US7265139B2 (en) * | 2001-03-08 | 2007-09-04 | Incyte San Diego Inc. | RXR activating molecules |
| ATE297910T1 (de) | 2001-03-14 | 2005-07-15 | Lilly Co Eli | Retinoid x rezeptormodulatoren |
| WO2002080935A1 (en) | 2001-04-04 | 2002-10-17 | Ortho Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| EP1421061A4 (en) * | 2001-08-17 | 2004-12-22 | Incyte San Diego Inc | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA |
| JP2005513026A (ja) * | 2001-11-15 | 2005-05-12 | インサイト サン ディエゴ インコーポレイテッド | 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環 |
| TW200304375A (en) * | 2001-12-06 | 2003-10-01 | Maxia Pharmaceuticals Inc | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer |
| US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US7102000B2 (en) * | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| JP4638423B2 (ja) * | 2003-06-20 | 2011-02-23 | ガルデルマ・リサーチ・アンド・デヴェロップメント | ＰＰＡＲγタイプ受容体を調節する新規化合物および化粧品組成物または医薬品組成物へのその使用 |
-
2002
- 2002-03-07 WO PCT/US2002/007001 patent/WO2002072009A2/en not_active Ceased
- 2002-03-07 MX MXPA03008117A patent/MXPA03008117A/es unknown
- 2002-03-07 US US10/094,142 patent/US7153875B2/en not_active Expired - Fee Related
- 2002-03-07 PL PL02373912A patent/PL373912A1/xx not_active Application Discontinuation
- 2002-03-07 CA CA002440184A patent/CA2440184A1/en not_active Abandoned
- 2002-03-07 EP EP02721289A patent/EP1385465A4/en not_active Withdrawn
- 2002-03-07 AU AU2002252227A patent/AU2002252227A1/en not_active Abandoned
- 2002-03-07 IL IL15774002A patent/IL157740A0/xx unknown
- 2002-03-07 BR BR0207846-5A patent/BR0207846A/pt not_active Application Discontinuation
- 2002-03-07 JP JP2002570969A patent/JP2005506290A/ja active Pending
- 2002-03-07 EA EA200300982A patent/EA200300982A1/ru unknown
-
2003
- 2003-09-02 NO NO20033883A patent/NO20033883L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506290A5 (enExample) | ||
| CN101784543B (zh) | 作为细胞坏死抑制剂的吲哚和吲唑化合物 | |
| AU2006214164B2 (en) | Isoxazole combretastin derivatives for the treatment of disorders | |
| JP6532607B2 (ja) | スルホンアミド化合物又はその塩 | |
| TWI222447B (en) | 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents | |
| JP2010538076A5 (enExample) | ||
| AU2016258192A1 (en) | K-Ras modulators | |
| RU2005121667A (ru) | 5-замещенные пиразиновые или пиридиновые активаторы глюкокиназы | |
| JP2007524696A5 (enExample) | ||
| JP2012530765A5 (enExample) | ||
| WO2005085241A1 (ja) | チアゾール誘導体 | |
| JP2013531055A5 (enExample) | ||
| AU2019345297B2 (en) | Treatment for non-alcoholic fatty liver disease | |
| US10889555B2 (en) | Sulfonamide compound or salt thereof | |
| US20100093670A1 (en) | Compounds for the treatment of angiogenesis | |
| CA2617991A1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| JP2010535706A5 (enExample) | ||
| KR101511771B1 (ko) | 세포괴사 저해제로서의 인돌 및 인다졸 화합물 | |
| CN110105340A (zh) | 苯甲酰胺和烟酰胺化合物及其使用方法 | |
| NZ562314A (en) | Compounds which inhibit beta-secretase activity and methods of use thereof | |
| CA2580265A1 (en) | Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof | |
| JP2004517151A5 (enExample) | ||
| JP2017516824A5 (enExample) | ||
| JP2003528098A5 (enExample) | ||
| JP2008516914A5 (enExample) |